APAC Obesity Pipeline Hits 30 Assets as Orforglipron and Two Asian Approvals Reshape GLP-1 Race
Thirty obesity and weight-management assets discovered by Asia-Pacific-headquartered companies are now in registered human trials, according to a BioPharma APAC year-end census with data current to 31 October 2026, and 21 of those molecules originated in mainland China. The same count records three APAC-originated products reaching a market during 2026 — orforglipron in the United States, ecnoglutide in China and efpeglenatide in Korea — a shift that moves the region from licensing source to commercial competitor in the GLP-1 peptide drug sector.
For the peptide therapy and research peptide industry, the census is a supply-side signal as much as a scientific one. A deeper bench of GLP-1, GIP and dual-agonist molecules originating in China, Korea, Japan and India implies more API demand, more finished-product capacity in vials and cartridges, and more pressure on clinics and telehealth operators to distinguish approved medicines from compounded and research-use-only materials. This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com.
What the BioPharma APAC census actually counted
The census applied two inclusion tests: the originator — the company that discovered the molecule — had to be headquartered in Asia-Pacific, and the asset needed at least one registered human trial in obesity or weight management on ClinicalTrials.gov, China’s drug trial registry or an equivalent. Licensing a molecule out did not change its origin classification. Semaglutide, reformulations and generics of already-approved molecules, and longevity-agent discussion were excluded by design.
By country, the 30 assets split into 21 from mainland China, six from Korea, two from Japan and one from India. The authors state they found no Australian, Taiwanese or Singaporean originated asset meeting the tests. Efficacy figures appear only where a sponsor has publicly disclosed them, taken from the most advanced completed trial at the longest disclosed timepoint, using the treatment-policy estimand where both estimands were given.
The three 2026 approvals and the filings behind them
Orforglipron, the oral pill discovered by Chugai and taken global by Eli Lilly, won US approval in April 2026. Sciwind’s ecnoglutide cleared China’s National Medical Products Administration for weight management in March 2026. Hanmi’s efpeglenatide became Korea’s first home-grown obesity drug in October 2026.
Behind those approvals, three Chinese GLP-1/GIP dual agonists have completed Phase 3 and are filed with the NMPA: HRS9531, olatorepatide and BGM0504. According to company disclosures compiled by BioPharma APAC, they reported weight reductions of 17.7%, 18.7% and 19.2% respectively at 48 to 52 weeks. The spread across the three — roughly 1.5 percentage points — is smaller than the difference between estimands within a single trial, which is why the publication cautions that its chart should not be read as a league table.
Two further Chinese dual agonists, RAY1225 and HDM1005, sit behind the filed trio; the full Phase 3 figures behind their announcements are still pending. Mazdutide, approved in China for weight management in June 2025, is Innovent’s commercial lead but an Eli Lilly molecule, so it fails the originator test and is excluded from the 30 — although its GLORY-2 trial reported −18.55% weight change at week 60 at the 9 mg dose, a useful reference point for the class.
Key numbers from the APAC obesity pipeline
| Metric | Figure | Status / source |
|---|---|---|
| APAC-discovered assets in registered human obesity trials | 30 (21 China, 6 Korea, 2 Japan, 1 India) | BioPharma APAC census, data to 31 Oct 2026 |
| APAC-originated approvals in 2026 | 3 (orforglipron, ecnoglutide, efpeglenatide) | Regulatory approvals, April / March / October 2026 |
| Chinese GLP-1/GIP duals filed with NMPA | 3 — HRS9531 17.7%, olatorepatide 18.7%, BGM0504 19.2% at 48–52 weeks | Sponsor disclosures, Phase 3 complete |
| Chinese once-daily oral GLP-1 pills | 3, roughly 10%–12.5% at 44–52 weeks | Phase 3 readouts, sponsor disclosures |
| Orforglipron oral efficacy | −11.2% at week 72 | Sponsor disclosure |
| Assets with ex-regional or global licensee / European partner | 13 of 30 | BioPharma APAC analysis |
| Disclosed upfront payments | ~USD 1.04 billion, before Menarini’s EUR 62 million | BioPharma APAC analysis |
Orals versus injectables: a convenience story, not an efficacy story
The census separates the two modalities by disclosed weight change. Three Chinese once-daily oral pills land between about 10% and 12.5% at 44 to 52 weeks, and the publication describes a reasonably tight band of −9.8% to −12.4% for once-daily small molecules — below the leading injectables. Orforglipron’s −11.2% at week 72 sits in a similar range.
Industry observers note that this gap shapes competitive strategy rather than closing the oral case. Pills are expected to compete on convenience, manufacturing cost and access rather than depth of weight loss. For peptide API manufacturers and fill-finish sites, that distinction matters: small-molecule oral GLP-1s do not consume peptide synthesis capacity at all, while oral peptide formats and injectables do. A market that tilts toward small-molecule pills could redirect demand away from solid-phase peptide synthesis lines and toward conventional chemical manufacturing.
Dosing interval is emerging as a second differentiator. Bofanglutide and RAY1225 are dosed every two weeks; zovaglutide and the GRADUAL-3 programme test monthly injections; ASC30, which Ascletis is taking through global Phase 3 itself, has a monthly depot. Bofanglutide, a mono-agonist given fortnightly, reports a one-year figure in the same band as the weekly duals — a result that, if it holds in the planned GRADUAL-2 trial against semaglutide, would suggest receptor mechanism matters less than many assumed. That remains conditional on data not yet reported.
Why this matters for peptide therapy clinics and research peptide supply
For clinics, telehealth platforms and medical spas that build programmes around GLP-1 peptides, the practical consequence is a widening gap between approved products and everything else. Approved medicines have undergone regulatory review for their approved uses; compounded drugs are prepared under specific legal conditions and are not FDA-approved as compounded products; research chemicals are intended for scientific use and should not be assumed suitable for human treatment. A crowded APAC pipeline increases the number of molecules patients will ask about — and the number that are still investigational, unapproved or research-use-only.
That makes verification a clinical workflow issue rather than a formality. Checking a product means searching the FDA’s Drugs@FDA database and official prescribing information by product name and active ingredient, then confirming the formulation, sponsor, approved indication and current labelling. A supplier’s statement, or the mere presence of an ingredient in a database, is not sufficient by itself. Prescription status and medical supervision remain the relevant frame for any approved GLP-1 medicine; research peptides are for research use only.
On the supply side, the licensing data show where the molecules are going. Of the 30 assets, 13 have an ex-regional or global licensee or a European partner. Disclosed upfront payments across Lilly, Kailera, Regeneron, Novo Nordisk, AstraZeneca, Merck, Verdiva, Genentech and Rhythm come to roughly USD 1.04 billion, before Menarini’s EUR 62 million. Hansoh alone has sold two obesity assets, to Regeneron and Merck. The notable unpartnered late-stage names are HDM1002, BGM0504, RAY1225 and HDM1005, plus ASC30.
For buyers tracking peptide API and finished-product capacity, that licensing map is a rough proxy for where manufacturing demand will land. PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates. Teams sourcing material should still evaluate documented product identity, batch-specific analytical data, impurity characterisation, manufacturing transparency, traceability and storage conditions — and should not treat a certificate of analysis as proof of clinical safety or sterility for administration.
Muscle preservation and the next research frontier
Two of the most valued early deals in the census are not incretins at all. Hanmi’s HM17321 with Genentech and Laekna’s clinical collaboration with Lilly both aim to protect lean mass during weight loss, and neither has disclosed a weight figure yet. The publication frames muscle preservation as the next frontier.
This is an early-stage research signal, not an established clinical benefit. No lean-mass or functional outcome data are cited in the census, and animal or mechanistic findings would not by themselves establish human efficacy. For research peptide suppliers and laboratories, the relevant takeaway is directional: combination strategies that pair incretin-driven weight loss with lean-mass preservation are attracting capital, which typically precedes demand for new tool compounds and analytical standards. Laboratories evaluating such materials should confirm exact sequence or chemical identity, salt form, modifications, molecular weight, stated quantity, purity method and batch documentation before treating two similarly named peptides as equivalent.
What comes next
The census flags a dense calendar of readouts. By the end of 2026, Verdiva’s EVOLVE-2 topline for once-weekly oral ecnoglutide and Dong-A ST’s DA-1726 Phase 1 Part 3 are expected. January 2027 brings the estimated completion of Hanmi’s HM15275 Phase 2. During 2027, Kailera plans a global Phase 2 of HRS-7535, Sun Pharma’s utreglutide Phase 2 is slated for the second half, and GRADUAL-2 against semaglutide is planned. In 2028, Kailera’s KaiNETIC global Phase 3 for HRS9531 and Ascletis’s AURORA topline for ASC30 are expected — described by the publication as the first pivotal tests of Chinese-originated obesity drugs in Western populations.
The analytical caveat travels with all of it. The figures are not yet comparable across trials, and the census chart should not be read as a league table. Different populations, estimands, trial durations and baseline characteristics limit cross-molecule comparison. What the census does establish is structural: a year ago, an Asia-Pacific obesity pipeline was mostly a licensing story; at the end of 2026 it includes a US-approved pill, two Asian approvals, three Chinese filings and a deep bench of Phase 3 readouts. For the peptide supply chain, the question is no longer whether APAC-originated incretins will reach Western markets, but which manufacturing, quality-documentation and distribution partners will be ready when they do.
FAQ
How many Asia-Pacific obesity drugs are in human trials?
BioPharma APAC counts 30 assets discovered by Asia-Pacific-headquartered originators in registered human obesity or weight-management trials as of 31 October 2026, including 21 from mainland China, six from Korea, two from Japan and one from India.
Which APAC-originated obesity drugs were approved in 2026?
Three: orforglipron received US approval in April 2026, Sciwind’s ecnoglutide was cleared by China’s NMPA in March 2026, and Hanmi’s efpeglenatide was approved in Korea in October 2026.
Are Chinese GLP-1/GIP dual agonists as effective as leading injectables?
HRS9531, olatorepatide and BGM0504 reported 17.7%, 18.7% and 19.2% weight reduction at 48 to 52 weeks in sponsor disclosures. These figures come from separate trials and are not directly comparable with each other or with other products; the census explicitly warns against reading them as a league table.
What should clinics check before offering a GLP-1 peptide?
Confirm the specific product’s approval status and labelling through the FDA’s Drugs@FDA database and official prescribing information, and distinguish approved medicines from compounded drugs and research-use-only materials. Prescription and medical supervision apply to approved GLP-1 medicines; research peptides are not approved treatments.